Search Results

The ChlamydiaTrol™ Ag is intended for use as an unassayed control reagent with in vitro diagnostic assay procedures for detection of Chlamydia trachomatis, including both chlamydial antigen (MOMP or LPS) and nucleic acid based methods of detection. ChlamydiaTrol Aq reagents are intended to provide a means of estimating precision and reproducibility, and have the potential for detecting systematic deviations from specific laboratory testing procedures. Use of ChlamydiaTrol Ag reagent will monitor assay functionality and not analytical sensitivity of the assay detection limits.

ChlamydiaTrol Ag is a liquid quality control reagent classified under Multi Analyte Controls(assayed and unassayed). ChlamydiaTrol Ag reagent is prepared from Chlamydia trachomatis elementary bodies extracted from infected mouse L cells grown in culture. Optimally infected cells are harvested and disrupted by sonication, and cellular debris is removed by centrifugation. Chlamydia trachomatis elementary bodies used in the preparation of ChlamydiaTrol Ag reagent have been rendered noninfectious by treatment with gamma radiation. The reagent contains human serum albumin(HSA), preservatives and stabilizers.

The provided text describes the acceptance criteria and study for ChlamydiaTrol™ Ag, a liquid unassayed quality control reagent for Chlamydia trachomatis antigen detection.

Here's an analysis of the provided information:

1. Table of Acceptance Criteria and Reported Device Performance

As an unassayed quality control reagent, ChlamydiaTrol Ag does not have assigned reference values or traditional analytical acceptance criteria like sensitivity, specificity, or accuracy compared to a gold standard. Instead, its performance is assessed based on its reactivity, reproducibility, and stability within various commercial Chlamydia trachomatis diagnostic kits. The acceptance criteria essentially revolve around demonstrating consistent and predictable performance as a control.

2. Sample Size Used for the Test Set and Data Provenance

• Clinical Evaluation Test Set:

  • Sample Size: Not explicitly stated as a single "sample size" of specimens. Instead, the study involved:
    • 2 different lots of ChlamydiaTrol Ag reagent.
    • Evaluated by eight clinical investigators (sites).
    • Using three different commercial test systems.
    • Each "result(n) for ChlamydiaTrol Ag represents a single determination" (Page 5, Section 5.2). The total number of runs/determinations varied among sites and test kit lots.
  • Data Provenance: Prospective, collected from June 1996 through May 1997 ("During the period from June, 1996 through May, 1997, two different lots of ChlamydiaTrol Ag reagent were evaluated by eight clinical investigators..." - Page 5, Section 5.0). The geographic origin of the clinical sites is not specified, but the submission is to the US FDA, implying US-based sites.

• Reproducibility Test Set (Within-run/Between-run):

  • Within-run: 20 replicates of the same sample.
  • Between-run: Single test results of the sample in multiple test runs.
  • Data Provenance: Not explicitly stated, likely internal Blackhawk BioSystems testing.

• Stress Testing (Temperature, Freeze/Thaw, Open Vial):

  • Sample Size: Not explicitly stated as number of replicates, but involved "two different lots of reagent" for temperature and open vial studies.
  • Data Provenance: Not explicitly stated, likely internal Blackhawk BioSystems testing.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

• N/A (Not Applicable): For this device, ground truth as typically defined (e.g., confirmed disease status) is not used. ChlamydiaTrol Ag is a quality control reagent, not a diagnostic device. Its "performance" is judged by its consistent and reproducible reactivity within various diagnostic assays, as monitored by the clinical laboratories themselves, rather than against a disease endpoint. The "ground truth" for its intended use is its ability to consistently produce a positive reaction within a laboratory's established range.

4. Adjudication Method (for the test set)

• N/A (Not Applicable): As a quality control reagent, there is no "ground truth" in the diagnostic sense to adjudicate against. The results reported by each site were analyzed to determine mean value, standard deviation, and coefficient of variation (Page 5, Section 5.1). Consistency across sites and methods serves as the metric of acceptable performance.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

• N/A (Not Applicable): This is not an AI-based diagnostic device and therefore an MRMC study comparing human readers with and without AI assistance is not relevant. The device is a liquid quality control reagent for Chlamydia trachomatis antigen tests.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

• N/A (Not Applicable): This is not an algorithm or AI device. It's a laboratory reagent. Its "standalone" performance relates to its inherent stability and reactivity, as demonstrated in the reproducibility and stress testing, but not in the context of an algorithm.

7. The type of ground truth used

• For this quality control reagent, the "ground truth" is its inherent property to produce a consistent and measurable positive signal within various commercial Chlamydia trachomatis antigen detection assays. This is affirmed by:
  • Batch consistency: Lots designed to produce a positive reaction within a target range.
  • Analytical reproducibility: Low coefficients of variation in repeated testing.
  • Stability over time and under stress conditions: Maintaining reactivity under various storage and handling conditions.
  • Consistency across different test methods and clinical sites: Showing comparable results when used with different commercial kits by different laboratories.

8. The sample size for the training set

• N/A (Not Applicable): This device is a biochemical reagent, not a machine learning model. Therefore, there is no "training set" in the context of AI/algorithms. The reagent itself is manufactured and formulated using Chlamydia trachomatis elementary bodies and human proteins.

9. How the ground truth for the training set was established

• N/A (Not Applicable): As there is no training set for an AI/algorithm, this question is not relevant. The quality of the manufactured reagent (e.g., the concentration of Chlamydia trachomatis elementary bodies and the formulation with stabilizers) is established through manufacturing processes and internal quality control, not by establishing a ground truth for a training set.

Ask a specific question about this device